Introduction
Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease, characterized by the presence of painful nodules and abscesses in apocrine gland-bearing areas (1) (2) (3) . The rupture of these lesions leads to the formation of sinus tracts and scarring, causing progressive worsening of the clinical prognosis (1, 2) . Furthermore, affected areas are frequently malodourous with recurrent purulent discharge (3) . As a consequence, patients with HS experience a substantial loss of quality of life (1, 4) .
Awareness of HS is still lacking among physicians, contributing to delayed diagnosis or, in extreme cases, to misdiagnosis (1, 5) . These gaps result in more advanced-stage patients, whose therapeutic options become progressively limited.
The primary aim of this study was to assess screening practices and awareness among general practitioner (GP) residents and consultants regarding HS characteristics and therapeutic approaches.
Methods
With the permission of Parsi et al. (6) and Costa-Silva et al. (7), we adapted a questionnaire and then distributed it to all GP residents and consultants attending two dermatology meetings dedicated to GPs in December 2015 and April 2016. Epidemiology, pathophysiology, diagnostic, and management questions regarding HS were adjusted and gathered together in this questionnaire.
For the results analysis, the participants were divided into three groups: GP residents in the first 2 years of residency, GP residents in the last 2 years of residency, and GP consultants. All statistical analyses were performed using SPSS version 20.0 (IBM, Armonk, NY). Categorical variables were compared using Fisher's exact test or a chi-square test. We considered the significance level to be p < 0.05.
Results
The overall response rate was 62% (366 of 593), with 283 women (77%). Among the respondents, 187 were GP residents in their 1st year (51%), 84 in their 2nd year (23%), 58 in their 3rd year (16%), 21 in their 4th year (6%), and 16 were consultants (4%; Table 1 ). For a patient with boils and/or recurrent cysts located at folds, 327 considered a diagnosis of HS (90%), whereas 35 did not (10%), with no significant difference in the responses according to the years of experience (p = 0.429). In addition, 169 (46%) reported evaluating
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Finally, regarding acute HS treatment, 39% of the respondents prescribed non-steroidal anti-inflammatory drugs (NSAIDs), 59% abscess drainage, 9% oral contraceptives, 84% topical antibiotics, 7% topical retinoids, 2% oral retinoids, 76% oral antibiotics, 24% topical steroids, and 2% oral steroids (Table 3) . Regarding the therapeutic approach, we determined the following statistically significant differences among young residents, advanced residents, and consultants: treatment with NSAIDs is higher among older residents (51%) compared to younger ones (36%; p = 0.02), and the prescription of oral clindamycin is higher among consultants (31%) compared to residents (12%; p = 0.047; Table 4 ).
Discussion
Until recently, HS was considered an orphan disease because it was treated by several specialties, although it was assigned to none of them (8) . This fact may explain the estimated delay of 5 to 14 years in the diagnosis, which contributes to a deterioration of clinical status and a clear impairment in patients' quality of life (8) .
Several risk factors are recognized in the setting of HS. Tobacco smoking, for example, is linked with more severe and treatmentresistant disease (9) . Due to mechanical irritation, occlusion, and maceration, obesity is a demonstrated contributing factor for HS, and therapy with lithium is also a marked aggravator (10, 11) . Of note, the role of hormones in the pathophysiology of HS is still controversial, and hormonal fluctuations may merely be acting as a confounding factor (12) .
On the other hand, in recent years information has increased about HS-associated diseases, although their significance remains unclear (5). IBD, spondylarthritis, pyoderma gangrenosum, synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, and Behçet disease are recognized comorbid associations (2, 11) . Several endocrinal disorders have also been linked, including diabetes, acromegaly, and Cushing syndrome (2) . However, no pathogenic background has yet been suggested (2) .
Treatment of HS is influenced by numerous factors, including severity and extension of the disease, comorbidities, and patient age. Among topical agents, 15% resorcinol may be helpful, and among topical antibiotics clindamycin (0.1% twice daily) is the only option with a clear benefit (3, 13) . In moderate to severe cases, systemic therapies are usually required. Systemic antibiotics with a proven benefit include clindamycin (300 mg twice daily) plus rifampicin (300 mg twice daily), clindamycin in monotherapy, or tetracycline (13) . According to recent data, isotretinoin is not recommended in the treatment of HS, but acitretin may be an option in selected cases (13) . Oral corticosteroids should be reserved for acute flares and for short periods, and intralesional therapy may be especially useful for recalcitrant lesions (13) . For moderate to severe HS without response to previous drugs, biological agents may be considered (13) . Of note, NSAIDs have no proven benefits in the relief of pain and inflammation (13) .
Surgery is the only definite treatment for HS, mainly when there are sinus tracts and scars (3). Radical excision is considered the treatment of choice for these patients, although wide surgical in-IBD = inflammatory bowel disease, GPs = general practitioners. NSAIDs = non-steroidal anti-inflammatory drugs, GPs = general practitioners. GP awareness toward hidradenitis suppurativa tervention may be disfiguring and, ultimately, does not prevent recurrences (3, 13) . Regarding incision and drainage, this technique results in rapid pain relief, but it is not generally recommended in the treatment of solid inflamed nodules, mostly because there is a high rate of recurrences (3). In our study, 84% of the responders considered topical antibiotics and 76% systemic antibiotics as the treatment of choice for HS. In a previous study by Benhadou et al., Belgian and Danish GPs considered systemic antibiotics the best drug option (14) . Drainage was proposed by 59% of our responders, whereas Belgian and Danish GPs are weaker advocates (20% and 8%, respectively) of this therapeutic intervention (14) .
The majority of GP trainees and consultants recognized HS as an independent entity and confirmed observing several patients per month. However, there seems to be a lack of knowledge concerning disease associations and, most importantly, current therapeutic strategies. During residency, there are few differences in attitudes regarding patients with HS, pointing to gaps in the residency program.
Our study has some limitations. First, there is a potential reporting bias naturally related to the questionnaire-based methodology. Second, there is a difference between the categorized groups, with a small proportion of GP consultants, which may influence the analysis. Finally, there was a 28% rate of non-responders in our study. There are several possible explanations for this finding: non-responders may not be interested in this issue or they may lack of knowledge about HS and therefore have chosen not to respond.
GPs must play a key role not only in early diagnosis but also in therapeutic decisions and in controlling comorbidities of patients with HS. To us, it seems crucial to promote the development of skills on this issue, so that a referral to dermatology is made correctly and with the appropriate timing whenever first-line measures are insufficient.
